Millennium Management LLC Has $1.94 Million Holdings in Kamada Ltd. (NASDAQ:KMDA)

Millennium Management LLC reduced its stake in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 317,904 shares of the biotechnology company's stock after selling 36,872 shares during the quarter. Millennium Management LLC owned approximately 0.55% of Kamada worth $1,936,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in KMDA. Aristides Capital LLC raised its position in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after acquiring an additional 6,850 shares in the last quarter. Geode Capital Management LLC raised its position in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after acquiring an additional 1,549 shares in the last quarter. NewEdge Advisors LLC raised its position in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after acquiring an additional 8,260 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Kamada during the fourth quarter valued at approximately $67,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KMDA has been the topic of several recent research reports. Sidoti raised shares of Kamada to a "hold" rating in a research report on Thursday, May 8th. Wall Street Zen raised shares of Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Benchmark reaffirmed a "buy" rating and set a $15.00 price objective on shares of Kamada in a research report on Thursday, May 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Kamada presently has an average rating of "Buy" and an average target price of $14.67.

Kamada Stock Down 1.0%

Shares of NASDAQ:KMDA traded down $0.07 during trading on Wednesday, reaching $6.66. The stock had a trading volume of 38,150 shares, compared to its average volume of 91,198. Kamada Ltd. has a 52 week low of $4.74 and a 52 week high of $9.16. The firm has a market capitalization of $382.82 million, a price-to-earnings ratio of 23.79, a P/E/G ratio of 0.97 and a beta of 0.94. The stock has a fifty day simple moving average of $6.57 and a two-hundred day simple moving average of $6.67.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07. Kamada had a net margin of 9.92% and a return on equity of 6.30%. The company had revenue of $44.02 million for the quarter, compared to analyst estimates of $154.06 million. On average, analysts forecast that Kamada Ltd. will post 0.23 EPS for the current year.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.